Phase I Study of PF-07799933 (ARRY-440) as Monotherapy or in Combination in Participants With Advanced Solid Tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
September 12, 2023
End Date
November 15, 2023
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
September 12, 2023
End Date
November 15, 2023